Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
Hannah Louise Zakariassen, Linu M. John, Thomas A. Lutz
Basic & Clinical Pharmacology & Toxicology (2020) Vol. 127, Iss. 3, pp. 163-177
Open Access | Times Cited: 21

Showing 21 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco, et al.
The Lancet (2021) Vol. 398, Iss. 10317, pp. 2160-2172
Open Access | Times Cited: 139
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 93
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
David S. Mathiesen, Asger Lund, Tina Vilsbøll, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 56
A structural basis for amylin receptor phenotype
Jianjun Cao, Matthew J. Belousoff, Yi-Lynn Liang, et al.
Science (2022) Vol. 375, Iss. 6587
Closed Access | Times Cited: 47
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Creating the amylin story
Thomas A. Lutz
Appetite (2022) Vol. 172, pp. 105965-105965
Open Access | Times Cited: 33
Mediators of Amylin Action in Metabolic Control
Christina N. Boyle, Yi Zheng, Thomas A. Lutz
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2207-2207
Open Access | Times Cited: 33
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 417-440
Open Access | Times Cited: 40
Pharmacological characterisation of mouse calcitonin and calcitonin receptor‐like receptors reveals differences compared with human receptors
Michael L. Garelja, Rebekah L. Bower, Margaret A. Brimble, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 3, pp. 416-434
Open Access | Times Cited: 28
From the pancreas to the amygdala: new brain area critical for ingestive and motivated behavior control exerted by amylin.
Suyeun Byun, Ivana Marić, Stina Börchers, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 112040-112040
Open Access
The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity
Giulia Mazzini, Christelle Le Foll, Christina N. Boyle, et al.
Biophysical Chemistry (2024) Vol. 308, pp. 107201-107201
Open Access | Times Cited: 2
Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects
Igor Rubinić, Marija Kurtov, Robert Likić
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 2
ASB4 modulates central melanocortinergic neurons and calcitonin signaling to control satiety and glucose homeostasis
Eirini Vagena, Jasmina Crneta, Pauline Engström, et al.
Science Signaling (2022) Vol. 15, Iss. 733
Closed Access | Times Cited: 12
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
David S. Mathiesen, Asger Lund, Jens J. Holst, et al.
European Journal of Endocrinology (2022) Vol. 186, Iss. 6, pp. R93-R111
Open Access | Times Cited: 11
Structural insight into selectivity of amylin and calcitonin receptor agonists
Jianjun Cao, Matthew J. Belousoff, Elliot Gerrard, et al.
Nature Chemical Biology (2023) Vol. 20, Iss. 2, pp. 162-169
Open Access | Times Cited: 6
A new era in gut hormone-based pharmacotherapy for people with obesity
Chloe Firman, Rachel L. Batterham
Proceedings of The Nutrition Society (2022) Vol. 81, Iss. 3, pp. 217-226
Open Access | Times Cited: 6
Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors
Sang Min Lee
Biomolecules (2021) Vol. 11, Iss. 9, pp. 1364-1364
Open Access | Times Cited: 8
The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats
Lauren M. Stein, Lauren E. McGrath, Rinzin Lhamo, et al.
AJP Regulatory Integrative and Comparative Physiology (2021) Vol. 321, Iss. 2, pp. R250-R259
Open Access | Times Cited: 6
Hindbrain REV-ERB nuclear receptors regulate sensitivity to diet-induced obesity and brown adipose tissue pathophysiology
Lauren N. Woodie, Lily C. Melink, Ahren J. Alberto, et al.
Molecular Metabolism (2023) Vol. 79, pp. 101861-101861
Open Access
Structure-based insight into development of selective and non-selective amylin and calcitonin receptor agonists
Jianjun Cao, Matthew J. Belousoff, Radostin Danev, et al.
Research Square (Research Square) (2022)
Open Access
Page 1

Scroll to top